[1]
|
张之南,单渊东,李蓉生,等. 协和血液病学[M]. 北京:中国协和医科大学出版社,2004:497. |
[2]
|
Roodman GD. Pathogenesis of myeloma bone disease[J]. Blood Cells Mol Dis, 2004, 32:290-292. doi: 10.1016/j.bcmd.2004.01.001 |
[3]
|
Dimopoulos M, Terpos E, Comenzo RL, et al. International Myeloma Working Group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma[J]. Leukemia, 2009, 23:1545-1556. doi: 10.1038/leu.2009.89 |
[4]
|
Derlin T, Bannas P. Imaging of multiple myeloma:current concepts[J]. World J Orthop, 2014, 5:272-282. doi: 10.5312/wjo.v5.i3.272 |
[5]
|
Regelink JC, Minnema MC, Terpos E, et al. Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease:a systematic review[J]. Br J Haematol, 2013, 162:50-61. doi: 10.1111/bjh.12346 |
[6]
|
Horger M, Claussen CD, Bross-Bach U, et al. Whole-body low-dose multidetector row-CT in the diagnosis of multiple myeloma:an alternative to conventional radiography[J]. Eur J Radiol, 2005, 54:289-297. doi: 10.1016/j.ejrad.2004.04.015 |
[7]
|
Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma[J]. Lancet Oncol, 2014, 15:538-548. doi: 10.1016/S1470-2045(14)70442-5 |
[8]
|
Baur-Melnyk A, Buhmann S, Becker C, et al. Whole-body MRI versus whole-body MDCT for staging of multiple myeloma[J]. AJR Am J Roentgenol, 2008, 190:1097-1104. doi: 10.2214/AJR.07.2635 |
[9]
|
Dimopoulos MA, Hillengass J, Usmani S, et al. Role of magnetic resonance imaging in the management of patients with multiple myeloma:a consensus statement[J]. J Clin Oncol, 2015, 33:657-664. doi: 10.1200/JCO.2014.57.9961 |
[10]
|
Walker R, Barlogie B, Haessler J, et al. Magnetic res-onance imaging in multiple myeloma:diagnostic and clinical implications[J]. J Clin Oncol, 2007, 25:1121-1128. doi: 10.1200/JCO.2006.08.5803 |
[11]
|
Hillengass J, Bäuerle T, Bartl R, et al. Diffusion-weighted imaging for non- invasive and quantitative monitoring of bone marrow infiltration in patients with monoclonal plasma cell disease:a comparative study with histology[J]. Br J Haematol, 2011, 153:721-728. doi: 10.1111/j.1365-2141.2011.08658.x |
[12]
|
Rasche L, Alapat D, Kumar M, et al. Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma[J]. Leukemia, 2019, 33:1713-1722. doi: 10.1038/s41375-018-0329-0 |
[13]
|
Cavo M, Terpos E, Nanni C, et al. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders:a consensus statement by the International Myeloma Working Group[J]. Lancet Oncol, 2017, 18:206-217. doi: 10.1016/S1470-2045(17)30189-4 |
[14]
|
Usmani SZ, Mitchell A, Waheed S, et al. Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3[J]. Blood, 2013, 121:1819-1823. doi: 10.1182/blood-2012-08-451690 |
[15]
|
Zamagni E, Patriarca F, Nanni C, et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation[J]. Blood, 2011, 118:5989-5995. doi: 10.1182/blood-2011-06-361386 |
[16]
|
Zamagni E, Nanni C, Mancuso K, et al. PET/CT Improves the definition of complete response and allows to detect otherwise unidentifiable skeletal progression in multiple myeloma[J]. Clin Cancer Res, 2015, 21:4384-4390. doi: 10.1158/1078-0432.CCR-15-0396 |
[17]
|
Puig N, Sarasquete ME, Balanzategui A, et al. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry[J]. Leukemia, 2014, 28:391. doi: 10.1038/leu.2013.217 |
[18]
|
Martinez-Lopez J, Lahuerta JJ, Pepin F, et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma[J]. Blood, 2014, 123:3073-3079. doi: 10.1182/blood-2014-01-550020 |
[19]
|
Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA):a randomised, open-label, phase 3 study[J]. Lancet,2019,394:29-38. doi: 10.1016/S0140-6736(19)31240-1 |
[20]
|
金媛媛,庄俊玲.新药时代自体造血干细胞移植在多发性骨髓瘤一线治疗中的地位[J].协和医学杂志,2018,9:219-223. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=xhyx201803007 |
[21]
|
Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma[J]. Lancet Oncol, 2016, 17:e328-e346. doi: 10.1016/S1470-2045(16)30206-6 |
[22]
|
Rasche L, Angtuaco E, MC Donald JE, et al. Low expression of Hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma[J]. Blood, 2017, 130:30-34. doi: 10.1182/blood-2017-03-774422 |
[23]
|
Lapa C, Garcia-Velloso MJ, Lückerath K, et al. 11C-Methionine-PET in multiple myeloma:a combined study from two different institutions[J]. Theranostics, 2017, 7:2956-2964. doi: 10.7150/thno.20491 |
[24]
|
Philipp-Abbrederis K, Herrmann K, Knop S, et al. In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma[J]. EMBO Mol Med, 2015, 7:477-487. doi: 10.15252/emmm.201404698 |